Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | DDO | Q99489 | 1/20 | 0.47 |
| ▸ | AHR | P35869 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 2/20 | 0.40 |
| ▸ | ITK | Q08881 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.35 |
| ▸ | ALPI | P09923 | 1/20 | 0.35 |
| ▸ | ALPG | P10696 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12574858 | 0.85 | KDM4E (0.47) | DAOAHRMEN1KMT2AFLT3 | |
| SCHEMBL27659521 | 0.82 | DAO (0.49) | DAODDOAHRMEN1KMT2A | |
| SCHEMBL22024963 | 0.79 | CYP1A1 (0.36) | DAOAHRFLT3KDM4ENR3C1 | |
| SCHEMBL4568034 | 0.78 | DAO (0.49) | DAODDOMEN1KMT2AFLT3 | |
| SCHEMBL4568037 | 0.78 | DAO (0.49) | DAOAHRFLT3HPGD | |
| SCHEMBL8957566 | 0.78 | KIF11 (0.46) | FLT3ITKHPGD | |
| SCHEMBL2993745 | 0.78 | KEAP1 (0.52) | DAODDOAHRMEN1KMT2A | |
| SCHEMBL398009 | 0.77 | CYP2A6 (0.44) | MEN1KMT2AKDM4EHPGDKEAP1 | |
| SCHEMBL3705264 | 0.77 | TYR (0.47) | DAODDOFLT3KDM4EHPGD | |
| SCHEMBL26262426 | 0.76 | GPR84 (0.42) | KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-11 | — | — | US | disclosed |
| US-20230295115-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2023-09-21 | — | — | US | disclosed |
| US-20230295115-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (CA) | 2023-09-21 | — | — | US | disclosed |
| US-20210032207-A1 | QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-02-04 | — | — | US | disclosed |
| US-20200055823-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2020-02-20 | — | — | US | disclosed |
| US-20190077762-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2019-03-14 | — | — | US | disclosed |
| US-20170362180-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2017-12-21 | — | — | US | disclosed |
| US-20160340314-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2016-11-24 | — | — | US | disclosed |
| US-9440951-B2 | Quinolone compound | OTSUKA PHARMACEUTICAL CO., LTD (JP) | 2016-09-13 | — | — | US | disclosed |
| US-20150239865-A1 | QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2015-08-27 | — | — | US | disclosed |
| US-9067887-B2 | Quinolone compound | OTSUKA PHARMACEUTICAL CO., LTD (JP) | 2015-06-30 | — | — | US | disclosed |
| EP-2474530-B1 | INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-20140179675-A1 | QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-06-26 | — | — | US | disclosed |
| EP-2474530-A1 | INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20110105389-A1 | Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the Same | OCERA THERAPEUTICS, INC. | 2011-05-05 | — | — | US | disclosed |
| US-20090131492-A1 | Indole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239865-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | DAO 297/4885DDO 873/4885AHR 937/4885 |
| US-20170362180-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | DAO 297/4885DDO 873/4885AHR 937/4885 |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, LTB4R | DAO 3529/4885DDO 4687/4885AHR 933/4885 |
| US-20200055823-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | DAO 297/4885DDO 873/4885AHR 937/4885 |
| US-20160340314-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | DAO 297/4885DDO 873/4885AHR 937/4885 |
| US-20110105389-A1 | Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the Same | GHSR, GHRHR, GIPR | DAO 3732/4885DDO 2855/4885AHR 427/4885 |
| US-20240228504-A1 | SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | SLC10A1, NR1H4, SLC10A2 | DAO 69/4885DDO 303/4885AHR 138/4885 |
| US-20230295115-A1 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | HCCS, HAVCR2, HDGF | DAO 173/4885DDO 327/4885AHR 344/4885 |
| US-20090131492-A1 | Indole derivatives as CFTR modulators | CFTR, ABCB1, ABCB11 | DAO 2772/4885DDO 3868/4885AHR 80/4885 |
| US-20190077762-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | DAO 316/4885DDO 923/4885AHR 1011/4885 |
| US-20140179675-A1 | QUINOLONE COMPOUND | HAX1, NQO2, NHERF1 | DAO 297/4885DDO 873/4885AHR 937/4885 |
| US-20210032207-A1 | QUINOLONE COMPOUND | HAX1, NQO2, CXCR1 | DAO 264/4885DDO 914/4885AHR 1042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.